This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
The country has constantly worked with the spirit of public-private partnership
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Subscribe To Our Newsletter & Stay Updated
